Ovid Therapeutics Inc.
For the period ended Mar 31, 2026. Filed May 12, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 12, 2026
OVID$2.80-1.8%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Stockholders’ Equity
Condensed Consolidated Statements of Stockholders’ Equity (unaudited)
| (in thousands, except shares) · Series AConvertiblePreferred Stock · Common Stock · AdditionalPaid-In Capital · Accumulated Other Comprehensive Loss · Accumulated Deficit · Total | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares · Amount · Shares · Amount | ||||||||||||
| Balance, December 31, 2025 | — | $— | 130,184,353 | $130 | $452,445 | $(202) | $(321,713) | $130,660 | ||||
| Issuance of shares of common stock from sales under the ATM program, net of expenses | — | — | 1,500,000 | 2 | 2,365 | — | — | 2,367 | ||||
| Issuance of shares of common stock and pre-funded warrants from private placement financing | — | — | 19,154,321 | 19 | 59,981 | — | — | 60,000 | ||||
| Expenses related to the issuance of shares of common stock and pre-funded warrants from private placement financing | — | — | — | — | (3,816) | — | — | (3,816) | ||||
| Exercise of Series A warrants to shares of common stock and pre-funded warrants | — | — | 16,140,663 | 16 | 26,577 | — | — | 26,593 | ||||
| Expenses related to the exercise of Series A warrants to shares of common stock and pre-funded warrants | — | — | — | — | (1,593) | — | — | (1,593) | ||||
| Issuance of shares of common stock from exercise of stock options, employee stock purchase plan and vesting of RSU awards | — | — | 287,129 | — | 220 | — | — | 220 | ||||
| Stock-based compensation expense | — | — | — | — | 1,046 | — | — | 1,046 | ||||
| Other comprehensive loss | — | — | — | — | — | (220) | — | (220) | ||||
| Net loss | — | — | — | — | — | — | (16,988) | (16,988) | ||||
| Balance, March 31, 2026 | — | $— | 167,266,466 | $167 | $537,225 | $(422) | $(338,701) | $198,269 | ||||
| (in thousands, except shares) | Series AConvertiblePreferred Stock | Common Stock | AdditionalPaid-In Capital | AccumulatedOtherComprehensive Loss | Accumulated Deficit | Total | ||||||
| Shares · Amount · Shares · Amount | ||||||||||||
| Balance, December 31, 2024 | 1,250 | $— | 71,009,866 | $71 | $372,489 | $(35) | $(304,299) | $68,226 | ||||
| Issuance of common stock from exercise of stock options, employee stock purchase plan and vesting of RSU awards | — | — | 99,648 | — | 13 | — | — | 13 | ||||
| Stock-based compensation expense | — | — | — | — | 1,284 | — | — | 1,284 | ||||
| Other comprehensive loss | — | — | — | — | — | (12) | — | (12) | ||||
| Net loss | — | — | — | — | — | — | (10,235) | (10,235) | ||||
| Balance, March 31, 2025 | 1,250 | $— | 71,109,514 | $71 | $373,786 | $(47) | $(314,533) | $59,276 | ||||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.